Skip to main content
TipRanks
Go Ultimate75% OFF

JHS Svendgaard Laboratories Limited (JHS) AI Stock Analysis

1 Followers
IN:JHS

JHS Svendgaard Laboratories Limited

(NSE:JHS)

Select Model
Rating:57Neutral
Price Target:INR 8.50â–²(4.94% Upside)
Action:reiterated
Date:10/06/26

The overall score is heavily weighed down by severe fundamental weaknesses, specifically persistent net losses, cash burn, and a highly unattractive valuation (negative P/E). While the stock currently enjoys strong technical momentum and benefits from a highly conservative balance sheet with minimal debt, poor operational execution severely limits its long-term viability and mutes the final score.

Positive Factors
Low Financial LeverageLow leverage and a large equity-funded capital base reduce solvency pressure and preserve financial flexibility. This gives JHS more room to manage operating volatility and fund improvements without the balance-sheet burden associated with heavy borrowing.
Negative Factors
Persistent UnprofitabilityJHS remains loss-making in FY2026, with negative operating earnings and net margin despite improvement versus FY2025. Continued unprofitability limits internally generated capital, weakens returns on equity, and makes a sustained recovery dependent on further execution.

JHS Svendgaard Laboratories Limited (JHS) vs. iShares MSCI India ETF (INDA)

-40%-30%-20%-10%0%10%20%30%IN:JHS-21.28%INDA-4.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 704.49M
Dividend Yield
―
Average Volume (3M)
35.73K
Price to Earnings (P/E)
-56.3
Beta (1Y)
0.43
Revenue Growth
15.61%
EPS Growth
85.89%
Country
India
Employees
235
Sector
Consumer Defensive
Sector Strength
62
Industry
Household & Personal Products

JHS Svendgaard Laboratories Limited Business Overview & Revenue Model

Company Description

JHS Svendgaard Laboratories Limited, along with its associated companies, specializes in the manufacturing and sale of a diverse array of oral and dental hygiene products, catering to both adults and children throughout India. Their extensive product...

JHS Svendgaard Laboratories Limited Financial Statement Overview

Summary

A pristine balance sheet with exceptionally low leverage (0.085 D/E) provides a strong structural cushion, but overall financial execution remains poor. Five consecutive years of net losses, volatile profit margins, and deeply negative free cash flows significantly drag down the financial profile despite a recent rebound in top-line revenue.

Income Statement

35Negative

Balance Sheet

80Positive

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.08B1.02B919.97M698.06M840.82M854.91M
Gross Profit222.32M177.22M309.55M203.55M165.45M201.68M
EBITDA32.15M60.64M-39.92M33.78M-163.82M85.45M
Net Income-11.83M-19.22M-197.44M-40.58M-175.17M-40.52M
Balance Sheet
Total Assets2.16B2.15B2.01B1.97B2.28B2.22B
Cash, Cash Equivalents and Short-Term Investments49.26M191.00M200.16M94.56M386.51M80.19M
Total Debt142.44M148.51M64.58M51.29M155.09M61.82M
Total Liabilities395.40M405.49M284.41M271.70M543.87M269.46M
Stockholders Equity1.76B1.75B1.73B1.70B1.74B1.86B
Cash Flow
Free Cash Flow0-148.91M-157.11M-401.17M89.43M-158.75M
Operating Cash Flow0-20.97M-51.78M-85.84M232.86M-91.36M
Investing Cash Flow0-130.38M-220.18M-217.34M96.77M-46.97M
Financing Cash Flow0121.43M232.97M21.74M-9.00M-16.72M

JHS Svendgaard Laboratories Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price8.10

Price Trends

50DMA8.77Negative
100DMA8.34Negative
200DMA8.63Negative

Market Momentum

MACD-0.21Negative
RSI43.47Neutral
STOCH47.99Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Negative. The current price of 8.10 is below the 20-day moving average (MA) of 8.22, below the 50-day MA of 8.77, and below the 200-day MA of 8.63, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 43.47 is Neutral, neither overbought nor oversold. The STOCH value of 47.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JHS.

JHS Svendgaard Laboratories Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

IN:JHS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:EMAMILTDIN:EMAMILTD74OutperformINR 186.65B24.93―2.58%13.15%-1.27%
IN:COLPALIN:COLPAL72OutperformINR 482.77B35.48―2.70%8.72%2.71%
IN:GODREJCPIN:GODREJCP69NeutralINR 949.77B48.09―2.15%12.02%8.49%
IN:DABURIN:DABUR67NeutralINR 693.62B34.21―2.30%8.94%11.89%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
IN:HONASAIN:HONASA57NeutralINR 172.72B61.02―0.57%25.70%114.58%
IN:JHSIN:JHS57NeutralINR 707.99M-56.30――15.61%85.89%

* Consumer Defensive Sector Average

Performance Comparison

0%50%IN:JHSIN:COLPALIN:DABURIN:EMAMILTDIN:GODREJCPIN:HONASADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:JHS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:JHSJHS Svendgaard Laboratories Limited8.10-2.66-24.72%
IN:COLPALColgate-Palmolive (India) Limited1775.00-347.76-16.38%
IN:DABURDabur India Limited391.00-112.97-22.42%
IN:EMAMILTDEmami Limited425.10-75.83-15.14%
IN:GODREJCPGodrej Consumer Products Limited928.00-173.84-15.78%
IN:HONASAHonasa Consumer Limited529.35244.3385.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 06, 2026